The DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.
The dawn of vaccines for cancer prevention
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
A human homologue of the Drosophila Toll protein signals activation of adaptive immunity
Medzhitov, R., Preston-Hurlburt, P., & Janeway, C. A. (1997) · Nature · doi:10.1038/41131 · Cited by 5,590
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Projections of the cost of cancer care in the United States: 2010–2020
Mariotto, A. B., Robin Yabroff, K., Shao, Y., Feuer, E. J., & Brown, M. L. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq495 · Cited by 2,657
Myeloid-Derived Suppressor Cells
Gabrilovich, D. I. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0297 · Cited by 1,882
Regulatory T cells in cancer immunotherapy
Tanaka, A., & Sakaguchi, S. (2017) · Cell Research · doi:10.1038/cr.2016.151 · Cited by 1,860
Cheever, M. A., Allison, J. P., Ferris, A. S., Finn, O. J., Hastings, B. M., Hecht, T. T., Mellman, I., Prindiville, S. A., Viner, J. L., Weiner, L. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0737 · Cited by 1,388
Self-citationCombination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
Immunity to Methylcholanthrene-Induced Sarcomas
(1957) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/18.6.769 · Cited by 1,229
Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia
Kenter, G. G., Welters, M. J. P., Valentijn, A. R. P. M., Lowik, M. J. G., Berends-van der Meer, D. M. A., Vloon, A. P. G., Essahsah, F., Fathers, L. M., Offringa, R., Drijfhout, J. W., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810097 · Cited by 1,102
Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
Formenti, S. C., & Demaria, S. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs629 · Cited by 1,053
Targeting neoantigens to augment antitumour immunity
Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.154 · Cited by 997
Dendritic-Cell-Based Therapeutic Cancer Vaccines
Palucka, K., & Banchereau, J. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.004 · Cited by 869
Schmielau, J., & Finn, O. J. (2001) · PubMed · Cited by 867
Self-citationMarchand, M., van Baren, N., Weynants, P., Brichard, V., Dr�no, B., Tessier, M.-H., Rankin, E., Parmiani, G., Arienti, F., Humblet, Y., et al. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990118)80:2<219::aid-ijc10>3.0.co;2-s · Cited by 784
De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation
Ghoneim, H. E., Fan, Y., Moustaki, A., Abdelsamed, H. A., Dash, P., Dogra, P., Carter, R., Awad, W., Neale, G., Thomas, P. G., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.007 · Cited by 781
A review of clinical trials of human papillomavirus prophylactic vaccines
Schiller, J. T., Castellsagué, X., & Garland, S. M. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.04.108 · Cited by 747
Klein, G., Sjögren, H. O., Klein, E., & Hellström, K. E. (1960) · PubMed · Cited by 742
Trimble, C. L., Morrow, M. P., Kraynyak, K. A., Shen, X., Dallas, M., Yan, J., Edwards, L., Parker, R. L., Denny, L., Giffear, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00239-1 · Cited by 727
Lehtinen, M., Paavonen, J., Wheeler, C. M., Jaisamrarn, U., Garland, S. M., Castellsagué, X., Skinner, S. R., Apter, D., Naud, P., Salmerón, J., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70286-8 · Cited by 704
Cancer vaccines: between the idea and the reality
Finn, O. J. (2003) · Nature Reviews Immunology · doi:10.1038/nri1150 · Cited by 636
Self-citationHossain, F., Al-Khami, A. A., Wyczechowska, D., Hernandez, C., Zheng, L., Reiss, K., Valle, L. D., Trillo-Tinoco, J., Maj, T., Zou, W., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0036 · Cited by 588
Immunology of Experimental Tumors
Old, L. J., & Boyse, E. A. (1964) · Annual Review of Medicine · doi:10.1146/annurev.me.15.020164.001123 · Cited by 496
Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1
Vacchelli, E., Ma, Y., Baracco, E. E., Sistigu, A., Enot, D. P., Pietrocola, F., Yang, H., Adjemian, S., Chaba, K., Semeraro, M., et al. (2015) · Science · doi:10.1126/science.aad0779 · Cited by 452
HPV vaccines – A review of the first decade
Harper, D. M., & DeMars, L. R. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.04.004 · Cited by 429
New adjuvants for human vaccines
Mbow, M. L., De Gregorio, E., Valiante, N. M., & Rappuoli, R. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.04.004 · Cited by 406
Prevalence of HPV After Introduction of the Vaccination Program in the United States
Markowitz, L. E., Liu, G., Hariri, S., Steinau, M., Dunne, E. F., & Unger, E. R. (2016) · Pediatrics · doi:10.1542/peds.2015-1968 · Cited by 383
Requirements for global elimination of hepatitis B: a modelling study
Nayagam, S., Thursz, M., Sicuri, E., Conteh, L., Wiktor, S., Low-Beer, D., & Hallett, T. B. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30204-3 · Cited by 373
Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity
Flint, T. R., Janowitz, T., Connell, C. M., Roberts, E. W., Denton, A. E., Coll, A. P., Jodrell, D. I., & Fearon, D. T. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.10.010 · Cited by 367
Tumor-induced perturbations of cytokines and immune cell networks
Burkholder, B., Huang, R.-Y., Burgess, R., Luo, S., Jones, V. S., Zhang, W., Lv, Z.-Q., Gao, C.-Y., Wang, B.-L., Zhang, Y.-M., et al. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.01.004 · Cited by 356
Immunological Surveillance in Neoplasia
Burnet, F. M. (1971) · Immunological Reviews · doi:10.1111/j.1600-065x.1971.tb00461.x · Cited by 342
Integrating next-generation dendritic cell vaccines into the current cancer immunotherapy landscape
Garg, A. D., Coulie, P. G., Van den Eynde, B. J., & Agostinis, P. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.05.006 · Cited by 340
Vaccines for tumour prevention
Lollini, P.-L., Cavallo, F., Nanni, P., & Forni, G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1815 · Cited by 340
Disis, M. L., Grabstein, K. H., Sleath, P. R., & Cheever, M. A. (1999) · PubMed · Cited by 340
Mier, J. W., & Gallo, R. C. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.10.6134 · Cited by 298
A Phase I Trial of a Synthetic Mucin Peptide Vaccine
Goydos, J. S., Elder, E., Whiteside, T. L., Finn, O. J., & Lotze, M. T. (1996) · Journal of Surgical Research · doi:10.1006/jsre.1996.0264 · Cited by 275
Self-citationCzerniecki, B. J., Koski, G. K., Koldovsky, U., Xu, S., Cohen, P. A., Mick, R., Nisenbaum, H., Pasha, T., Xu, M., Fox, K. R., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4038 · Cited by 266
Kimura, T., McKolanis, J. R., Dzubinski, L. A., Islam, K., Potter, D. M., Salazar, A. M., Schoen, R. E., & Finn, O. J. (2013) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-12-0275 · Cited by 263
Self-citationLong-term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer
Chang, M.-H., You, S.-L., Chen, C.-J., Liu, C.-J., Lai, M.-W., Wu, T.-C., Wu, S.-F., Lee, C.-M., Yang, S.-S., Chu, H.-C., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.05.048 · Cited by 258
Steinman, R. M., Adams, J. C., & Cohn, Z. A. (1975) · The Journal of experimental medicine · doi:10.1084/jem.141.4.804 · Cited by 237
Viral vector-based therapeutic cancer vaccines
Larocca, C., & Schlom, J. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e3182325e63 · Cited by 222
Lai, P., Rabinowich, H., Crowley‐Nowick, P. A., Bell, M. C., Mantovani, G., & Whiteside, T. L. (1996) · PubMed · Cited by 218
Genes Coding for Tumor Antigens Recognized by Cytolytic T Lymphocytes
Pel, A. V., Van Der Bruggen, P., Coulie, P. G., Brichard, V. G., Lethéa, B., Van Den Eynde, B., Uyttenhove, C., Renauld, J., & Boon, T. (1995) · Immunological Reviews · doi:10.1111/j.1600-065x.1995.tb00084.x · Cited by 218
Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses
Welters, M. J., van der Sluis, T. C., van Meir, H., Loof, N. M., van Ham, V. J., van Duikeren, S., Santegoets, S. J., Arens, R., de Kam, M. L., Cohen, A. F., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad8307 · Cited by 216
On immunosurveillance in human cancer.
Thomas, L. (1982) · PubMed Central · Cited by 213
Blixt, O., Bueti, D., Burford, B., Allen, D., Julien, S., Hollingsworth, M., Gammerman, A., Fentiman, I., Taylor-Papadimitriou, J., & Burchell, J. M. (2011) · Breast Cancer Research · doi:10.1186/bcr2841 · Cited by 211
The Human Vaccines Project: A roadmap for cancer vaccine development
Romero, P., Banchereau, J., Bhardwaj, N., Cockett, M., Disis, M. L., Dranoff, G., Gilboa, E., Hammond, S. A., Hershberg, R., Korman, A. J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf0685 · Cited by 194
Inducing autoimmune disease to treat cancer
Pardoll, D. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5340 · Cited by 183
Steller, M. A., Gurski, K. J., Murakami, M., Daniel, R. W., Shah, K. V., Celis, E., Sette, A., Trimble, E. L., Park, R. C., & Marincola, F. M. (1998) · PubMed · Cited by 175
Carbone, D. P., Ciernik, I. F., Kelley, M. J., Smith, M. C., Nadaf, S., Kavanaugh, D., Maher, V. E., Stipanov, M., Contois, D., Johnson, B. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.158 · Cited by 169
van Poelgeest, M. I. E., Welters, M. J. P., Vermeij, R., Stynenbosch, L. F. M., Loof, N. M., Berends-van der Meer, D. M. A., Löwik, M. J. G., Hamming, I. L. E., van Esch, E. M. G., Hellebrekers, B. W. J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2594 · Cited by 167
Sharma, A., Koldovsky, U., Xu, S., Mick, R., Roses, R., Fitzpatrick, E., Weinstein, S., Nisenbaum, H., Levine, B. L., Fox, K., et al. (2012) · Cancer · doi:10.1002/cncr.26734 · Cited by 164
Transforming Cancer Prevention through Precision Medicine and Immune-oncology
Kensler, T. W., Spira, A. E., Garber, J. E., Szabo, E. M., Lee, J. J., Dong, Z., Dannenberg, A. J., Hait, W. N., Blackburn, E. H., Davidson, N. E., et al. (2016) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-15-0406 · Cited by 158
The immune microenvironment of breast ductal carcinoma in situ
Thompson, E. D., Taube, J. M., Elwood, H. R., Sharma, R. B., Meeker, A. K., Warzecha, H. N., Argani, P., Cimino‐Mathews, A., & Emens, L. A. (2016) · Modern Pathology · doi:10.1038/modpathol.2015.158 · Cited by 151
Holmgaard, R., Zamarin, D., Lesokhin, A. M., Merghoub, T., & Wolchok, J. D. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.02.024 · Cited by 148
Precancer Atlas to Drive Precision Prevention Trials
Spira, A. E., Yurgelun, M. B. B., Alexandrov, L. B., Rao, A., Bejar, R., Polyák, K., Giannakis, M., Shilatifard, A., Finn, O. J., Dhodapkar, M., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2346 · Cited by 141
Self-citationCramer, D. W., Titus-Ernstoff, L. T., McKolanis, J., Welch, W. R., Vitonis, A. F., Berkowitz, R. S., & Finn, O. J. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0035 · Cited by 139
Self-citationTherapeutic vaccination against human papilloma virus induced malignancies
van der Burg, S. H., & Melief, C. J. M. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.12.010 · Cited by 139
The immune regulation in cancer by the amino acid metabolizing enzymes ARG and IDO
Mondanelli, G., Ugel, S., Grohmann, U., & Bronte, V. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.05.002 · Cited by 138
Ferrara, A., Nonn, M., Sehr, P. A., Schreckenberger, C., Pawlita, M., D�rst, M., Schneider, A., & Kaufmann, A. M. (2003) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-003-0463-5 · Cited by 137
Morelli, A. B., Becher, D., Koernig, S., Silva, A., Drane, D. P., & Maraskovsky, E. (2012) · Journal of Medical Microbiology · doi:10.1099/jmm.0.040857-0 · Cited by 135
Dhodapkar, M. V., Sexton, R., Das, R., Dhodapkar, K. M., Zhang, L., Sundaram, R. K., Soni, S., Crowley, J. J., Orlowski, R. Z., & Barlogie, B. (2015) · Blood · doi:10.1182/blood-2015-03-632919 · Cited by 127
Human Tumor Antigens Yesterday, Today, and Tomorrow
Finn, O. J. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0112 · Cited by 119
Self-citationHatam, L., DeVoti, J. A., Rosenthal, D. W., Lam, F., Abramson, A. L., Steinberg, B. M., & Bonagura, V. R. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2941 · Cited by 115
Cancer Prevention: Obstacles, Challenges, and the Road Ahead
Meyskens, F. L., Mukhtar, H., Rock, C. L., Cuzick, J. M., Kensler, T. W., Yang, C. S., Ramsey, S. D., Lippman, S. M., & Alberts, D. S. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv309 · Cited by 114
Suzuki, H., Graziano, D. F., McKolanis, J., & Finn, O. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0538 · Cited by 113
Self-citationPosuwan, N., Wanlapakorn, N., Sa‐nguanmoo, P., Wasitthankasem, R., Vichaiwattana, P., Klinfueng, S., Vuthitanachot, V., Saelao, S., Foonoi, M., Fakthongyoo, A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150499 · Cited by 112
Finn, O. J., & Forni, G. (2002) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00317-5 · Cited by 107
Self-citationThe potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer
Guo, T. W., Eisele, D. W., & Fakhry, C. (2016) · Cancer · doi:10.1002/cncr.29992 · Cited by 105
Modulation of Cancer-Specific Immune Responses by Amino Acid Degrading Enzymes
Timosenko, E., Hadjinicolaou, A. V., & Cerundolo, V. (2016) · Immunotherapy · doi:10.2217/imt-2016-0118 · Cited by 105
MUC1 immunotherapy is here to stay
Kimura, T., & Finn, O. J. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.725719 · Cited by 102
Self-citationChanging global policy to deliver safe, equitable and affordable care for women's cancers
Ginsburg, O., Badwe, R., Boyle, P., Derricks, G., Dare, A., Evans, T., Eniu, A., Jimenez, J., Kutluk, T., Lopes, G., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31393-9 · Cited by 102
Molecular cancer prevention: Current status and future directions
Maresso, K. C., Tsai, K. Y., Brown, P. H., Szabo, E. M., Lippman, S. M., & Hawk, E. T. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21287 · Cited by 100
Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective
Rivière, I., & Sadelain, M. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.034 · Cited by 100
Twelve-year survival and immune correlates in dendritic cell–vaccinated melanoma patients
Groß, S., Erdmann, M., Haendle, I., Voland, S., Berger, T. G., Schultz, E. S., Strasser, E. F., Dankerl, P., Janka, R., Schliep, S., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.91438 · Cited by 92
Cyclin B1 and Other Cyclins as Tumor Antigens in Immunosurveillance and Immunotherapy of Cancer
Egloff, A. M., Vella, L. A., & Finn, O. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3389 · Cited by 91
Self-citationLive-attenuated bacteria as a cancer vaccine vector
Toussaint, B., Chauchet, X., Wang, Y., Polack, B., & Gouëllec, A. L. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2013.836914 · Cited by 91
Epidemiologic perspective on immune-surveillance in cancer
Cramer, D. W., & Finn, O. J. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.01.002 · Cited by 81
Self-citationHuman Tumor Antigens Are Ready to Fly
Henderson, R. A., & Finn, O. J. (1996) · Advances in immunology · doi:10.1016/s0065-2776(08)60431-9 · Cited by 78
Self-citationTriggering Intracellular Receptors for Vaccine Adjuvantation
Gutjahr, A., Tiraby, G., Pérouzel, É., Verrier, B., & Paul, S. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.07.001 · Cited by 77
From Antigen Delivery System to Adjuvanticy: The Board Application of Nanoparticles in Vaccinology
Boraschi, D., & Italiani, P. (2015) · Vaccines · doi:10.3390/vaccines3040930 · Cited by 75
Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors
Karaki, S., Anson, M., Tran, T., Giusti, D., Blanc, C., Oudard, S. M., & Tartour, É. (2016) · Vaccines · doi:10.3390/vaccines4040037 · Cited by 73
Karlsson, J., Andréasson, B., Kondori, N., Erman, E., Riesbeck, K., Hogevik, H., & Wennerås, C. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00021-11 · Cited by 71
Vaccines for Cancer Prevention: A Practical and Feasible Approach to the Cancer Epidemic
Finn, O. J. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0110 · Cited by 69
Self-citationNovel “Elements” of Immune Suppression within the Tumor Microenvironment
Gurusamy, D., Clever, D. C., Eil, R. L., & Restifo, N. P. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0117 · Cited by 65
Vella, L. A., Yu, M., Fuhrmann, S. R., El-Amine, M., Epperson, D. E., & Finn, O. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903225106 · Cited by 59
Self-citationPejawar‐Gaddy, S., Rajawat, Y. S., Hilioti, Z., Jia, X., Gaddy, D. F., Finn, O. J., Viscidi, R. P., & Bossis, I. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0895-0 · Cited by 59
Self-citationÖhman, J. N., Magnusson, B., Telemo, E., Jontell, M., & Hasséus, B. (2012) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2012.02701.x · Cited by 58
Finn, O. J., & Beatty, P. L. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.01.002 · Cited by 58
Self-citationTowards a vaccine to prevent cancer in Lynch syndrome patients
Doeberitz, M. V. K., & Kloor, M. (2013) · Familial Cancer · doi:10.1007/s10689-013-9662-7 · Cited by 57
Burford, B., Gentry‐Maharaj, A., Graham, R. A., Allen, D., Pedersen, J. W., Nudelman, A. S., Blixt, O., Fourkala, E.-O., Bueti, D., Dawnay, A., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.214 · Cited by 55
A U.S. “Cancer Moonshot” to accelerate cancer research
Singer, D. S., Jacks, T., & Jaffee, E. M. (2016) · Science · doi:10.1126/science.aai7862 · Cited by 55
Mumps and ovarian cancer: modern interpretation of an historic association
Cramer, D. W., Vitonis, A. F., Pinheiro, S. P., McKolanis, J., Fichorova, R. N., Brown, K. E., Hatchette, T. F., & Finn, O. J. (2010) · Cancer Causes & Control · doi:10.1007/s10552-010-9546-1 · Cited by 54
Self-citationmRNA Cancer Vaccines—Messages that Prevail
Grunwitz, C. R., & Kranz, L. M. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_509 · Cited by 54
Premalignant Lesions as Targets for Cancer Vaccines
Finn, O. J. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20031787 · Cited by 53
Self-citationImmunologic approaches to cancer prevention—current status, challenges, and future perspectives
Wojtowicz, M. E., Dunn, B. K., & Umar, A. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.11.001 · Cited by 53
Protective effect of naturally occurring anti-HER2 autoantibodies on breast cancer
Tabuchi, Y., Shimoda, M., Kagara, N., Naoi, Y., Tanei, T., Shimomura, A., Shimazu, K., Kim, S. J., & Noguchi, S. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3801-4 · Cited by 52
Beatty, P. L., van der Geest, R., Hashash, J. G., Kimura, T., Gutkin, D. W., Brand, R. E., & Finn, O. J. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1838-1 · Cited by 49
Self-citationHagan, T., & Pulendran, B. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028894 · Cited by 48
Gray, A., Raff, A. B., Chiriva‐Internati, M., Chen, S., & Kast, W. M. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00605.x · Cited by 46
Tumor-rejection antigens recognized by T lymphocytes
Finn, O. J. (1993) · Current Opinion in Immunology · doi:10.1016/0952-7915(93)90124-b · Cited by 43
Self-citationChu, N. J., Armstrong, T. D., & Jaffee, E. M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1186 · Cited by 43
Nocera, N. F., Lee, M. C., Cruz, L. M. D. L., Rosemblit, C., & Czerniecki, B. J. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00356 · Cited by 41
Chen, Y., Panarelli, N. C., Piotti, K. C., & Yantiss, R. K. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0124 · Cited by 39
Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines
Vreeland, T. J., Clifton, G. T., Herbert, G. S., Hale, D. F., Jackson, D. O., Berry, J. S., & Peoples, G. E. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2016.1202114 · Cited by 35
Linehan, D. C., Goedegebuure, P. S., & Eberlein, T. J. (1996) · Annals of Surgical Oncology · doi:10.1007/bf02305804 · Cited by 34
Gjertsen, M., Sæterdal, I., Sæbøe‐Larssen, S., & Gaudernack, G. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-002-0390-y · Cited by 29
Broussard, E. K., Kim, R., Wiley, J. C., Márquez-Manríquez, J. P., Annis, J. E., Pritchard, D. K., & Disis, M. L. (2013) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-12-0484 · Cited by 28
Redirecting the focus of cancer immunotherapy to premalignant conditions
Young, M. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.01.022 · Cited by 28
Identification and optimization of a novel series of indoleamine 2,3-dioxygenase inhibitors
Markwalder, J. A., Seitz, S. P., Blat, Y., Elkin, L. L., Hunt, J. T., Pabalan, J. G., Jure‐Kunkel, M., Vite, G. D., & Covello, K. L. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.12.015 · Cited by 27
Harnessing host immune responses to preneoplasia: promise and challenges
Dhodapkar, M. V. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0607-8 · Cited by 25
Qiu, S.-J., Lü, L., Qiao, C., Wang, L., Wang, Z., Xiao, X., Qian, S., Fung, J. J., Ye, S.-L., & Bonham, C. A. (2005) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0616-1 · Cited by 19
Janowitz, T., Lu, L., Yan, H., & Shyam-Sundar, V. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s65963 · Cited by 19
A decade in the life of tumor immunology.
Finn, O. J., & Lotze, M. T. (2001) · PubMed · Cited by 17
Self-citationMcCaskill‐Stevens, W., Pearson, D. C., Kramer, B. S., Ford, L. G., & Lippman, S. M. (2016) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-16-0230 · Cited by 14
Lutz, M., Worschech, A., Alb, M., Gahn, S., Bernhard, L., Schwab, M. G., Obermeier, S., Einsele, H., Kämmerer, U., Heuschmann, P. U., et al. (2014) · Blood · doi:10.1182/blood-2014-09-601302 · Cited by 13
Human Papillomavirus Vaccine for Cancer Prevention
Finn, O. J., & Edwards, R. P. (2009) · New England Journal of Medicine · doi:10.1056/nejme0907480 · Cited by 12
Self-citationCancer Care and Control as a Human Right: Recognizing Global Oncology as an Academic Field
Eniu, A. E., Martei, Y. M., Trimble, E. L., & Shulman, L. N. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175251 · Cited by 12
Disease Interception: Myths, Mountains, and Mole Hills
Hait, W. N., & Lebowitz, P. F. (2016) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-16-0049 · Cited by 9
Romo‐González, T., Esquivel‐Velázquez, M., Ostoa‐Saloma, P., Lara, C., Zentella‐Dehesa, A., León-Díaz, R., Lamoyi, E., & Larralde, C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119014 · Cited by 6
Cited by
De Ruysscher, D., Niedermann, G., Burnet, N. G., Siva, S., Lee, A. W. M., & Hegi-Johnson, F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0064-5 · Cited by 868
Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect
Rodríguez-Ruiz, M. E., Vanpouille-Box, C., Melero, I., Formenti, S. C., & Demaria, S. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.06.001 · Cited by 497
Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets
Zhang, S., Xiao, X., Yi, Y., Wang, X., Zhu, L., Shen, Y., Lin, D., & Wu, C. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01848-7 · Cited by 399
Dendritic cells as orchestrators of anticancer immunity and immunotherapy
Heras-Murillo, I., Adán-Barrientos, I., Galán, M., Wculek, S. K., & Sancho, D. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00859-1 · Cited by 383
Cancer vaccines: Building a bridge over troubled waters
Sellars, M. C., Wu, C. J., & Fritsch, E. F. (2022) · Cell · doi:10.1016/j.cell.2022.06.035 · Cited by 318
Metadata
- Authors
- Finn, O. J.
- Venue
- Nature Reviews Immunology
- Published
- 2017-12-27
- Volume
- 18
- Issue
- 3
- Pages
- 183-194
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2778958106
- Cited by
- 254
- References
- 125
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.